Dehghani Payam, Schmidt Christian W, Garcia Santiago, Okeson Brynn, Grines Cindy L, Singh Avneet, Patel Rajan A G, Wiley Jose, Htun Wah Wah, Nayak Keshav R, Alraies M Chadi, Ghasemzadeh Nima, Davidson Laura J, Acharya Deepak, Stone Jay, Alyousef Tareq, Case Brian C, Dai Xuming, Hafiz Abdul Moiz, Madan Mina, Jaffer Faoruc A, Shavadia Jay S, Garberich Ross, Bagai Akshay, Singh Jyotpal, Aronow Herbert D, Mercado Nestor, Henry Timothy D
Prairie Vascular Research Inc, Regina, Saskatchewan, Canada.
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
J Soc Cardiovasc Angiogr Interv. 2022 Sep-Oct;1(5):100404. doi: 10.1016/j.jscai.2022.100404. Epub 2022 Jul 9.
In-hospital mortality in patients with ST-segment elevation myocardial infarction (STEMI) is higher in those with COVID-19 than in those without COVID-19. The factors that predispose to this mortality rate and their relative contribution are poorly understood. This study developed a risk score inclusive of clinical variables to predict in-hospital mortality in patients with COVID-19 and STEMI.
Baseline demographic, clinical, and procedural data from patients in the North American COVID-19 Myocardial Infarction registry were extracted. Univariable logistic regression was performed using candidate predictor variables, and multivariable logistic regression was performed using backward stepwise selection to identify independent predictors of in-hospital mortality. Independent predictors were assigned a weighted integer, with the sum of the integers yielding the total risk score for each patient.
In-hospital mortality occurred in 118 of 425 (28%) patients. Eight variables present at the time of STEMI diagnosis (respiratory rate of >35 breaths/min, cardiogenic shock, oxygen saturation of <93%, age of >55 years, infiltrates on chest x-ray, kidney disease, diabetes, and dyspnea) were assigned a weighted integer. In-hospital mortality increased exponentially with increasing integer risk score (Cochran-Armitage χ, < .001), and the model demonstrated good discriminative power (c-statistic = 0.81) and calibration (Hosmer-Lemeshow, = .40). The increasing risk score was strongly associated with in-hospital mortality (3.6%-60% mortality for low-risk and very high-risk score categories, respectively).
The risk of in-hospital mortality in patients with COVID-19 and STEMI can be accurately predicted and discriminated using readily available clinical information.
ST段抬高型心肌梗死(STEMI)合并新型冠状病毒肺炎(COVID-19)患者的院内死亡率高于未合并COVID-19的患者。导致这种死亡率的因素及其相对贡献尚不清楚。本研究开发了一种包含临床变量的风险评分,以预测COVID-19合并STEMI患者的院内死亡率。
提取北美COVID-19心肌梗死登记处患者的基线人口统计学、临床和手术数据。使用候选预测变量进行单变量逻辑回归,并使用向后逐步选择进行多变量逻辑回归,以确定院内死亡率的独立预测因素。为独立预测因素分配一个加权整数,这些整数的总和即为每位患者的总风险评分。
425例患者中有118例(28%)发生院内死亡。STEMI诊断时存在的8个变量(呼吸频率>35次/分钟、心源性休克、血氧饱和度<93%、年龄>55岁、胸部X线有浸润影、肾病、糖尿病和呼吸困难)被分配了一个加权整数。院内死亡率随整数风险评分的增加呈指数增长( Cochr an-Armitage χ,<0.001),该模型具有良好的鉴别能力(c统计量=0.81)和校准度(Hosmer-Lemeshow,=0.40)。风险评分的增加与院内死亡率密切相关(低风险和极高风险评分类别死亡率分别为3.6%和60%)。
使用现成的临床信息可以准确预测和区分COVID-19合并STEMI患者的院内死亡风险。